Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw

K. M. Kim, W. Park, S. Y. Oh, H. J. Kim, W. Nam, Sungkil Lim, Yumie Rhee, Inho Cha

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Summary: The administration of teriparatide (TPTD) in conjunction with periodontal care could provide faster and more favorable clinical outcomes in previously refractory bisphosphonate-related osteonecrosis of the jaws (BRONJ) cases compared to conventional dental care, combination of surgery and antimicrobial treatment. We also found that underlying vitamin D levels might influence the response to TPTD treatment. Introduction: Treatment of BRONJ is quite challenging and there are no standard treatment modalities. In this retrospective, longitudinal study, we examined whether additional TPTD administration could be beneficial for the resolution of BRONJ lesions compared to conservative management, such as antimicrobial treatment with or without surgery, and also studied the factors influencing the response to TPTD. Methods: Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group. All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months. Results: While 60.0 % of the non-TPTD group showed one stage of improvement in BRONJ, 40.0 % of the group did not show any improvement in disease status. In the TPTD group, 62.5 % of the treated subjects showed one stage of improvement and the other 37.5 % demonstrated a marked improvement, including two stages of improvement or complete healing, and there was not a single case that did not improve. The clinical improvement of BRONJ was statistically better in the TPTD group after the 6-month treatment (p∈<∈0.05). Moreover, patients with higher baseline serum 25(OH)D levels showed better clinical therapeutic outcomes with TPTD. Conclusions: We observed the beneficial effects of TPTD on BRONJ, and subjects with optimal serum vitamin D concentrations seemed to reap the maximum therapeutic effects of TPTD. A prospective, randomized, controlled trial should be needed to further evaluate the therapeutic efficacy of TPTD in the resolution of BRONJ.

Original languageEnglish
Pages (from-to)1625-1632
Number of pages8
JournalOsteoporosis International
Volume25
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Teriparatide
Therapeutics
Vitamin D
Dental Care
Therapeutic Uses
Subcutaneous Injections

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{c87efda6a7e24dd7a0a84d5488ad29aa,
title = "Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw",
abstract = "Summary: The administration of teriparatide (TPTD) in conjunction with periodontal care could provide faster and more favorable clinical outcomes in previously refractory bisphosphonate-related osteonecrosis of the jaws (BRONJ) cases compared to conventional dental care, combination of surgery and antimicrobial treatment. We also found that underlying vitamin D levels might influence the response to TPTD treatment. Introduction: Treatment of BRONJ is quite challenging and there are no standard treatment modalities. In this retrospective, longitudinal study, we examined whether additional TPTD administration could be beneficial for the resolution of BRONJ lesions compared to conservative management, such as antimicrobial treatment with or without surgery, and also studied the factors influencing the response to TPTD. Methods: Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group. All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months. Results: While 60.0 {\%} of the non-TPTD group showed one stage of improvement in BRONJ, 40.0 {\%} of the group did not show any improvement in disease status. In the TPTD group, 62.5 {\%} of the treated subjects showed one stage of improvement and the other 37.5 {\%} demonstrated a marked improvement, including two stages of improvement or complete healing, and there was not a single case that did not improve. The clinical improvement of BRONJ was statistically better in the TPTD group after the 6-month treatment (p∈<∈0.05). Moreover, patients with higher baseline serum 25(OH)D levels showed better clinical therapeutic outcomes with TPTD. Conclusions: We observed the beneficial effects of TPTD on BRONJ, and subjects with optimal serum vitamin D concentrations seemed to reap the maximum therapeutic effects of TPTD. A prospective, randomized, controlled trial should be needed to further evaluate the therapeutic efficacy of TPTD in the resolution of BRONJ.",
author = "Kim, {K. M.} and W. Park and Oh, {S. Y.} and Kim, {H. J.} and W. Nam and Sungkil Lim and Yumie Rhee and Inho Cha",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00198-014-2622-8",
language = "English",
volume = "25",
pages = "1625--1632",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "5",

}

Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. / Kim, K. M.; Park, W.; Oh, S. Y.; Kim, H. J.; Nam, W.; Lim, Sungkil; Rhee, Yumie; Cha, Inho.

In: Osteoporosis International, Vol. 25, No. 5, 01.01.2014, p. 1625-1632.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw

AU - Kim, K. M.

AU - Park, W.

AU - Oh, S. Y.

AU - Kim, H. J.

AU - Nam, W.

AU - Lim, Sungkil

AU - Rhee, Yumie

AU - Cha, Inho

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Summary: The administration of teriparatide (TPTD) in conjunction with periodontal care could provide faster and more favorable clinical outcomes in previously refractory bisphosphonate-related osteonecrosis of the jaws (BRONJ) cases compared to conventional dental care, combination of surgery and antimicrobial treatment. We also found that underlying vitamin D levels might influence the response to TPTD treatment. Introduction: Treatment of BRONJ is quite challenging and there are no standard treatment modalities. In this retrospective, longitudinal study, we examined whether additional TPTD administration could be beneficial for the resolution of BRONJ lesions compared to conservative management, such as antimicrobial treatment with or without surgery, and also studied the factors influencing the response to TPTD. Methods: Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group. All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months. Results: While 60.0 % of the non-TPTD group showed one stage of improvement in BRONJ, 40.0 % of the group did not show any improvement in disease status. In the TPTD group, 62.5 % of the treated subjects showed one stage of improvement and the other 37.5 % demonstrated a marked improvement, including two stages of improvement or complete healing, and there was not a single case that did not improve. The clinical improvement of BRONJ was statistically better in the TPTD group after the 6-month treatment (p∈<∈0.05). Moreover, patients with higher baseline serum 25(OH)D levels showed better clinical therapeutic outcomes with TPTD. Conclusions: We observed the beneficial effects of TPTD on BRONJ, and subjects with optimal serum vitamin D concentrations seemed to reap the maximum therapeutic effects of TPTD. A prospective, randomized, controlled trial should be needed to further evaluate the therapeutic efficacy of TPTD in the resolution of BRONJ.

AB - Summary: The administration of teriparatide (TPTD) in conjunction with periodontal care could provide faster and more favorable clinical outcomes in previously refractory bisphosphonate-related osteonecrosis of the jaws (BRONJ) cases compared to conventional dental care, combination of surgery and antimicrobial treatment. We also found that underlying vitamin D levels might influence the response to TPTD treatment. Introduction: Treatment of BRONJ is quite challenging and there are no standard treatment modalities. In this retrospective, longitudinal study, we examined whether additional TPTD administration could be beneficial for the resolution of BRONJ lesions compared to conservative management, such as antimicrobial treatment with or without surgery, and also studied the factors influencing the response to TPTD. Methods: Twenty-four cases of intractable BRONJ were included: 15 subjects were assigned to the TPTD group and the other 9 subjects, who refused TPTD administration, were assigned to the non-TPTD group. All subjects in both groups continued calcium and vitamin D supplementation and the TPTD group additionally received a daily subcutaneous injection of 20 μg TPTD for 6 months. Results: While 60.0 % of the non-TPTD group showed one stage of improvement in BRONJ, 40.0 % of the group did not show any improvement in disease status. In the TPTD group, 62.5 % of the treated subjects showed one stage of improvement and the other 37.5 % demonstrated a marked improvement, including two stages of improvement or complete healing, and there was not a single case that did not improve. The clinical improvement of BRONJ was statistically better in the TPTD group after the 6-month treatment (p∈<∈0.05). Moreover, patients with higher baseline serum 25(OH)D levels showed better clinical therapeutic outcomes with TPTD. Conclusions: We observed the beneficial effects of TPTD on BRONJ, and subjects with optimal serum vitamin D concentrations seemed to reap the maximum therapeutic effects of TPTD. A prospective, randomized, controlled trial should be needed to further evaluate the therapeutic efficacy of TPTD in the resolution of BRONJ.

UR - http://www.scopus.com/inward/record.url?scp=84899620843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899620843&partnerID=8YFLogxK

U2 - 10.1007/s00198-014-2622-8

DO - 10.1007/s00198-014-2622-8

M3 - Article

C2 - 24554340

AN - SCOPUS:84899620843

VL - 25

SP - 1625

EP - 1632

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 5

ER -